🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

642 results for “Lacuna Pharma Pty Ltd” Clear

  1. REGN7257

    Lacuna Pharma Pty Ltd

    Severe aplastic anemia (SAA)

    phase 2 small molecule active

    1 trial

  2. REGN7544, REGN7544 Matching Placebo

    Lacuna Pharma Pty Ltd

    Sepsis-Induced Hypotension

    phase 2 small molecule active

    1 trial

  3. REGV131, LNP1265

    Lacuna Pharma Pty Ltd

    Hemophilia B

    phase 2 small molecule active

    1 trial

  4. ROT-TDS, Neupro 8 mg/24 h transdermal patch, Neupro 8 mg/24 h transdermal patch

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  5. RTA 408 Capsule, 10 mg, Skyclarys 50 mg hard capsules, RTA 408 Capsule, 2.5 mg, Skyclarys 50 mg hard capsules

    Lacuna Pharma Pty Ltd

    Friedreich's ataxia

    phase 2 small molecule active

    1 trial

  6. RTP-026 Placebo, RTP-026

    Lacuna Pharma Pty Ltd

    Patients with ST-Elevation Myocardial Infarction (STEMI)

    phase 2 small molecule active

    1 trial

  7. Rilzabrutinib

    Lacuna Pharma Pty Ltd

    Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  8. SCD-044 Tablets 0.1mg, SCD-044 Tablets 0.6mg, SCD-044 Tablets 0.3mg, SCD-044 Tablets 1.0mg, placebo to match SCD-044 tablets

    Lacuna Pharma Pty Ltd

    atopic dermatitis

    phase 2 small molecule active

    1 trial

  9. SCD-044 Tablets 0.3mg, SCD-044 Tablets 0.6mg, SCD-044 Tablets 1.0mg, SCD-044 Tablets 0.1mg, placebo to match SCD-044 tablets

    Lacuna Pharma Pty Ltd

    moderate to severe plaque psoriasis

    phase 2 small molecule active

    1 trial

  10. SIROLIMUS, BEKEMV 300 mg concentrate for solution for infusion, SIROLIMUS, PREDNISONE, METHYLPREDNISOLONE SODIUM SUCCINATE, PARACETAMOL, Epysqli 300 mg concentrate for solution for infusion, PREDNISONE, DIPHENHYDRAMINE HYDROCHLORIDE, SIROLIMUS, PREDNISONE, RITUXIMAB, RITUXIMAB, ECULIZUMAB, BEKEMV 300 mg concentrate for solution for infusion, AAV9.LAMP2B, DIPHENHYDRAMINE HYDROCHLORIDE, PARACETAMOL, METHYLPREDNISOLONE SODIUM SUCCINATE, PREDNISONE, SIROLIMUS, BEKEMV 300 mg concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Danon Disease

    phase 2 small molecule active

    1 trial

  11. SIROLIMUS, SIROLIMUS

    Lacuna Pharma Pty Ltd

    Subjects diagnosed with port wine stains

    phase 2 small molecule active

    1 trial

  12. SODIUM CHLORIDE

    Lacuna Pharma Pty Ltd

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  13. SODIUM CHLORIDE SOLUTION 0.9%

    Lacuna Pharma Pty Ltd

    Acute Ischemic Stroke

    phase 2 small molecule active

    1 trial

  14. SODIUM CHLORIDE, MYDRIASERT, insert ophtalmique, 0.34 % tropicamide/ 2.5 % phenylephrine hydrochloride

    Lacuna Pharma Pty Ltd

    to obtain pre-operative mydriasis or for diagnostic purposes

    phase 2 small molecule active

    1 trial

  15. SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

    Lacuna Pharma Pty Ltd

    Hypercortisolism related to benign adrenal tumour

    phase 2 other active

    1 trial

  16. SPI-62_DF2

    Lacuna Pharma Pty Ltd

    Cushing's Syndrome

    phase 2 small molecule active

    1 trial

  17. SY-1425, AZACITIDINE

    Lacuna Pharma Pty Ltd

    Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS)

    phase 2 small molecule active

    1 trial

  18. Single-centre, randomised, double-blind, split-face comparative design clinical trial to evaluate the efficacy and safety of the topical formulation with 4% hydroquinone and 0,025% tretinoin versus the formulation with 4% hydroquinone in patients with facial melasma

    Lacuna Pharma Pty Ltd

    facial melasma

    phase 2 other active

    1 trial

  19. Sodium chloride Fresenius Kabi 0,9% infuzní roztok, Cerebrolysin 215,2mg/ml Injekční roztok

    Lacuna Pharma Pty Ltd

    Cerebral Autosomal Dominant Arteriopathy with subcortical Infarcts and Leukoencephalopathy (CADASIL)

    phase 2 small molecule active

    1 trial

  20. Stivarga 40 mg film-coated tablets, Tevimbra 100 mg concentrate for solution for infusion, OMTX705

    Lacuna Pharma Pty Ltd

    Advanced/metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  21. Sunvozertinib, Sunvozertinib

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  22. TAR-0520 Gel

    Lacuna Pharma Pty Ltd

    Taxanes-induced peripheral neuropathy

    phase 2 small molecule active

    1 trial

  23. TAR-0520 Gel

    Lacuna Pharma Pty Ltd

    Capecitabine-induced hand and foot syndrome

    phase 2 small molecule active

    1 trial

  24. TAR-0520 gel matching vehicle without active ingredients, TAR-0520 Gel

    Lacuna Pharma Pty Ltd

    EGFR inhibitor-induced folliculitis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources